^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FCRLB (Fc Receptor Like B)

    i
    Other names: FCRLB, Fc Receptor Like B, FREB-2, FCRL2, Fc Receptor-Like B, FCRLM2, FCRLY, Fc Receptor-Like And Mucin-Like Protein 2, Fc Receptor-Related Protein Y, Fc Receptor-Like Protein 2, FLJ31052, FREB2, FcRY, Fc Receptor Homolog Expressed In B Cells Protein 2, Fc Receptor Homolog Expressed In B-Cells Protein 2, Fc Receptor-Like And Mucin-Like 2, FCRY
    Associations

    News

    Trials
    over1year
    Multi-omics profiling and experimental verification of tertiary lymphoid structure-related genes: molecular subgroups, immune infiltration, and prognostic implications in lung adenocarcinoma. (PubMed, Front Immunol)
    Our in-depth investigation of TLS-RGs in LUAD revealed their possible contributions to the clinicopathological features, prognosis, and characteristics of TME. These findings underscore the potential of TLS-RGs as prognostic biomarkers and therapeutic targets for LUAD, thereby paving the way for personalized treatment strategies.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CLDN18 (Claudin 18) • BIRC3 (Baculoviral IAP repeat containing 3) • GBP1 (Guanylate Binding Protein 1) • FCRLB (Fc Receptor Like B) • S100P (S100 calcium binding protein P)
    almost2years
    Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. (PubMed, Int J Mol Sci)
    In the last few years, nivolumab has become the standard of care for advanced-stage lung cancer patients...We also demonstrated that abnormal expression of most of the markers comprising the genomic signature has an adverse influence on OS, making them significant markers for therapeutic decision-making. Additional prospective studies in larger series of patients are required to confirm the clinical utility of these biomarkers.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • CD73 (5'-Nucleotidase Ecto) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • NT5E (5'-Nucleotidase Ecto) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • HLA-B (Major Histocompatibility Complex, Class I, B) • GZMA (Granzyme A) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • TP73 (Tumor Protein P73) • FCRLB (Fc Receptor Like B) • NKG2D (killer cell lectin like receptor K1)
    |
    Opdivo (nivolumab)
    2years
    Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing (ASH 2023)
    Additionally, this approach led us to identify a series of potential new targets for MM patients, depicting a new scenario where each patient could be “screened” to identify the best molecule to be targeted. While further investigation is necessary to assess off-target toxicity and confirm clinical relevance, our analyses significantly streamline the search for tumor markers with a method potentially applicable to different malignancies, bringing us closer to identifying the best candidates for effective CAR therapy.
    IO biomarker
    |
    FGFR3 (Fibroblast growth factor receptor 3) • CD38 (CD38 Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • SDC1 (Syndecan 1) • CCND2 (Cyclin D2) • IR (Insulin receptor) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • MAF (MAF BZIP Transcription Factor) • CD59 (CD59 Molecule) • FCRLB (Fc Receptor Like B) • SLAMF7 (SLAM Family Member 7) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    FCGR2B expression
    over2years
    Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia (ASH 2023)
    Novel transcripts identified by PacBio IsoSeq analysis drive expression of key genes including the important MAPK/ERK regulator DUSP22, and FC receptor FCRLB that promotes survival of B-lymphocytes. Other genes of interest included modulators of chromatic accessibility. Our findings demonstrate important new insights into isoform usage associated with WM subtype in WM and provide novel insights into the underlying biology of the disease.
    IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22) • ARID5B (AT-Rich Interaction Domain 5B) • FCRLB (Fc Receptor Like B) • HDAC4 (Histone Deacetylase 4) • HDAC9 (Histone Deacetylase 9)
    |
    MYD88 mutation • CXCR4 mutation • MYD88 mutation + CXCR4 mutation • USP22 overexpression
    over2years
    Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer. (PubMed, Cardiovasc Toxicol)
    Finally, we validated the expression level of immune-related genes in breast cancer patients-derived cardiomyocytes with doxorubicin-induced cardiotoxicity and found that the level of RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes are consistently dysregulated. Our findings offered a basis for understanding the mechanism and pathogenesis of the cardiotoxicity caused by doxorubicin in breast cancer patients and predicted the interaction of immune-related potential biomarkers with doxorubicin.
    Journal • BRCA Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • BRCA (Breast cancer early onset) • BIRC3 (Baculoviral IAP repeat containing 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD200 (CD200 Molecule) • CD79A (CD79a Molecule) • GATA2 (GATA Binding Protein 2) • BTLA (B And T Lymphocyte Associated) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CPA3 (Carboxypeptidase A3) • FCRL1 (Fc Receptor Like 1) • LRP1 (LDL Receptor Related Protein 1) • MS4A1 (Membrane Spanning 4-Domains A1) • TCL1A (TCL1 Family AKT Coactivator A) • FCRLA (Fc Receptor Like A) • FCRLB (Fc Receptor Like B) • RAD9A (RAD9 Checkpoint Clamp Component A)
    |
    doxorubicin hydrochloride
    over2years
    Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p) (IASLC-WCLC 2023)
    In our small series with paired samples from MPM p, our integrated analysis with immune profile and genomic changes on MPM demonstrated that after systemic treatment there is a decrease of the number of TILs and downregulation of immune related genes. Larger validation cohorts are needed to determine the best treatment schedule considering dynamic changes of immune profile.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PAX5 (Paired Box 5) • CD163 (CD163 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCR7 (Chemokine (C-C motif) receptor 7) • FOXP3 (Forkhead Box P3) • FCRL1 (Fc Receptor Like 1) • FCRLB (Fc Receptor Like B)
    |
    TMB-L
    over3years
    A novel nomogram associated with regulatory T cells infiltration by weighted gene co-expression network analysis for predicting survival in patients with colon cancer. (PubMed, Eur Rev Med Pharmacol Sci)
    We constructed a four-gene signature for predicting the prognosis of patients with colon cancer, and further developed the nomogram together with TNM stage and age to improve the predictive efficacy.
    Journal
    |
    NRG1 (Neuregulin 1) • FCRLB (Fc Receptor Like B)